

Resource Summary Report

Generated by SPARC SAWG on Sep 16, 2026

Brighton Collaboration

RRID:SCR_004089

Type: Tool

Proper Citation

Brighton Collaboration (RRID:SCR_004089)

Resource Information

URL: <https://brightoncollaboration.org/>

Proper Citation: Brighton Collaboration (RRID:SCR_004089)

Description: A non-profit partnership and global research network providing high quality vaccine safety information. Their mission is to enhance the science of vaccine research by providing standardized, validated, and objective methods for monitoring safety profiles and benefit to risk ratios of vaccines. Products and services to promote high quality vaccine safety research include: * Standardized case definitions of adverse events following immunization * Guidelines for collection, analysis, and presentation of vaccine safety data * Template protocols for vaccine safety research * Automatic Case Classification Tool (ABC tool) * Library of vaccine safety publications * Links to high quality vaccine safety resources * Vaccine Safety Quarterly - Newsletter

Abbreviations: BC

Synonyms: Brighton

Resource Type: community building portal, controlled vocabulary, data or information resource, portal, protocol

Keywords: vaccine, safety, vaccine safety, adverse event, immunization, clinical

Related Condition: Adverse event following immunization

Availability: Account required

Resource Name: Brighton Collaboration

Resource ID: SCR_004089

Alternate IDs: nlx_158550

Record Creation Time: 20220129T080222+0000

Ratings and Alerts

No rating or validation information has been found for Brighton Collaboration.

No alerts have been found for Brighton Collaboration.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Chakraborty R, et al. (2025) Predictive assessment with outcomes of phrenic nerve study in Guillain-Barré syndrome: a prospective study. Journal of Yeungnam medical science, 42, 45.

Swartz A, et al. (2024) The perceived beauty of art is not strongly calibrated to the statistical regularities of real-world scenes. Scientific reports, 14(1), 19368.

Tewedaj ZD, et al. (2024) A retrospective analysis of the clinical profile and factors associated with mortality and poor hospital outcomes in adult Guillain-Barre syndrome patients. Scientific reports, 14(1), 15520.

Hsieh CY, et al. (2024) Validating ICD-10 Diagnosis Codes for Guillain-Barré Syndrome in Taiwan's National Health Insurance Claims Database. Clinical epidemiology, 16, 733.

Abbott SL, et al. (2023) Implementing a robust adverse event of special interest surveillance for novel oral polio vaccine type 2 rollout, Nigeria, March-July 2021. The Pan African medical journal, 45(Suppl 2), 6.

Estephan L, et al. (2023) A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine. Vaccine, 41(15), 2615.

Ahmad L, et al. (2022) COVID-19 and Guillain-Barré syndrome: A single-center prospective case series with a 1-year follow-up. Medicine, 101(30), e29704.

Sidow NO, et al. (2022) Intravenous immunoglobulin treatment with prognosis for the first six months of Guillain-Barré Syndrome in Somalia: Case series. Annals of medicine and surgery (2012), 84, 104816.

Hernandez LM, et al. (2022) A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus. Vaccine, 40(35), 5263.

Folegatti PM, et al. (2022) Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. *Vaccine*, 40(35), 5248.

Volkman A, et al. (2021) The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. *Vaccine*, 39(22), 3067.

Huppertz HI, et al. (2021) [Recommendations on the approach when unusual neurological symptoms occur in temporal association with vaccinations in childhood and adolescence]. *Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft für Kinderheilkunde*, 169(1), 62.

Appelshauser L, et al. (2020) Antiparaneuronal antibodies and IgG subclasses in acute autoimmune neuropathy. *Neurology(R) neuroimmunology & neuroinflammation*, 7(5).

Vera AM, et al. (2020) An Injury Prevention Program for Professional Ballet: A Randomized Controlled Investigation. *Orthopaedic journal of sports medicine*, 8(7), 2325967120937643.

Kochhar S, et al. (2020) The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. *Vaccine*, 38(35), 5734.

Kim D, et al. (2020) The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. *Vaccine*, 38(34), 5556.

Nikkheslat N, et al. (2020) Childhood trauma, HPA axis activity and antidepressant response in patients with depression. *Brain, behavior, and immunity*, 87, 229.

Rouse CE, et al. (2019) Postpartum endometritis and infection following incomplete or complete abortion: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. *Vaccine*, 37(52), 7585.

Pellegrin S, et al. (2019) Neonatal seizures: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*, 37(52), 7596.

Van de Ven NS, et al. (2019) Impact of musculoskeletal symptoms on physical functioning and quality of life among treated people with HIV in high and low resource settings: A case study of the UK and Zambia. *PloS one*, 14(5), e0216787.